Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546661 · ClinicalTrials.gov registry record · Phase 1
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
A Phase 1 study of Muscle-invasive Bladder Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 20
- Study locations
NCT02546661: Active Phase 1 study of Muscle-invasive Bladder Cancer, sponsored by AstraZeneca.
NCT02546661 is a Phase 1 study of Muscle-invasive Bladder Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 117 participants, below the 1,324-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02546661, a Phase 1 study of Muscle-invasive Bladder Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, Phase 1b study in patients with muscle invasive bladder cancer (MIBC) (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetics and anti-tumour activity of multiple agents as monotherapy and as combinations of different novel anti-cancer agents. The study will consist of a number of study modules (sub-studies), each evaluating the safety and tolerability of a specific agent or combination.
Primary Outcome
The frequency and nature of adverse events will be assessed in order to determine the safety and tolerability of AZD4547 monotherapy given orally to selected patients with MIBC who have progressed following prior therapy.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG AZD1775
- DRUG AZD4547
- DRUG MEDI4736
- DRUG Vistusertib
Study Locations (20)
Other
- Research Site - Bordeaux
- Research Site - Caen
- Research Site - Lyon
- Research Site - Marseille
- Research Site - Saint-Herblain
- Research Site - Toulouse
- Research Site - Badalona
- Research Site - Barcelona
New York
- Research Site - New York
- Research Site - New York
- Research Site - New York
California
- Research Site - Los Angeles
Connecticut
- Research Site - New Haven
Florida
- Research Site - Fort Myers
Ohio
- Research Site - Cleveland
Tennessee
- Research Site - Nashville
Alberta
- Research Site - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2016-12-28 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 1 |
What the registry record for NCT02546661 still lists
NCT02546661 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 1,324-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Muscle-invasive Bladder Cancer appearing as the primary indexed condition, and to 5 interventions - of which Olaparib is the first listed.
NCT02546661 names 20 study sites across 11 states, led by Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT02546661 about?
NCT02546661 is a clinical study titled "Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer". This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, Phase 1b study in patients with muscle invasive bladder cancer (MIBC) (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetic...
What is the current status of trial NCT02546661?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2016-12-28. Estimated completion is 2026-01-30.
What conditions does trial NCT02546661 study?
This clinical trial studies the following conditions: Muscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT02546661?
The interventions under investigation include: Olaparib (DRUG), AZD1775 (DRUG), AZD4547 (DRUG), MEDI4736 (DRUG), Vistusertib (DRUG).
Who is sponsoring clinical trial NCT02546661?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02546661 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02546661's enrollment target sits among peer trials
117 6th of 10 higher than 5 of 10 other Muscle-invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle-invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
Sample Collection for Ongoing Research and Product Evaluation Study
RECRUITING
-
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
RECRUITING · NA
-
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
ACTIVE NOT RECRUITING · Phase 3
-
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
ACTIVE NOT RECRUITING · Phase 3
-
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI